Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1226 in Mild to Moderate Cystic Fibrosis and Non-CF Bronchiectasis
NCT03903913Phase 2Unknown
- Sponsor
- SolAeroMed
- Start
- Aug 2019
- Primary completion
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of S-1226 in cystic fibrosis (CF) and bronchiectasis, sponsored by SolAeroMed. Primary endpoint: Treatment-emergent adverse events at 60 minutes. Status: unknown.
02
Drugs
S-1226
03
Conditions
cystic fibrosis (CF)bronchiectasis
Beyond the preview
Go deeper on NCT03903913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03903913.